Mirae Asset Global Etfs Holdings Ltd. Arcutis Biotherapeutics, Inc. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $43.4 Billion
- Q1 2025
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 71,417 shares of ARQT stock, worth $964,843. This represents 0.0% of its overall portfolio holdings.
Number of Shares
71,417
Previous 69,354
2.97%
Holding current value
$964,843
Previous $966,000
15.53%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding ARQT
# of Institutions
252Shares Held
126MCall Options Held
605KPut Options Held
170K-
Suvretta Capital Management, LLC New York, NY11.4MShares$154 Million7.82% of portfolio
-
Jennison Associates LLC11.4MShares$153 Million0.13% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$148 Million4.91% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$119 Million8.65% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$116 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $813M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...